Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a board meeting scheduled for March 24, 2025, to approve and release the company’s annual results for the year ending December 31, 2024. Following the announcement, a conference call with management will be held to discuss the results, indicating the company’s commitment to transparency and stakeholder engagement.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and manufacturing biopharmaceutical products, with a market presence in Hong Kong.
YTD Price Performance: 49.91%
Average Trading Volume: 339,400
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$54.55B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue